Core Viewpoint - Guangzhou Pharmaceutical Group has taken a significant strategic step by establishing a "Brand Strategy Committee" and forming a "Brand Strategy Consulting Expert Think Tank" to enhance its brand building efforts, aiming to become a world-class enterprise during the "14th Five-Year Plan" period [1][4]. Group 1: Strategic Initiatives - The establishment of the Brand Strategy Consulting Expert Think Tank marks a transition from "top-level design" to "comprehensive implementation" in brand building, leveraging external expertise for long-term brand development [4]. - The think tank consists of ten top experts from various fields, creating a high-level intellectual matrix that covers the entire brand construction chain [6]. Group 2: Expert Contributions - Key members of the think tank include Zhang Guohua, who provides policy support, and media representatives like Xu Wei and Peng Haowen, who will help connect domestic and international markets [8]. - Academic leaders such as Ding Junjie and Zhang Zhian will offer theoretical foundations for brand management, while experts like Xu Youjie will integrate ESG principles into the brand's core [9][10]. Group 3: Brand Strategy Framework - The "1+6" brand strategy management framework includes a comprehensive brand strategy plan and six strategic initiatives, which will be supported by the think tank's experts [12][14]. - The establishment of the "National Advertising Research Institute Brand Demonstration Construction (Guangzhou) Practice Base" will facilitate the transformation of research outcomes into practical applications [14]. Group 4: Collaborative Ecosystem - The collaboration between the think tank, the newly launched "Guangzhou Pharmaceutical Brand Academy," and strategic partnerships with major media platforms aims to enhance brand management capabilities and foster a culture of innovation [15][16]. - This ecosystem will not only support immediate brand strategy implementation but also lay a solid intellectual foundation for the company's long-term sustainable development [19].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司收購浙江省醫藥工業有限公司100%股權的進展公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2026年3月3日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2026－010 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 12 月 17 日，广州白云山医药集团股份有 ...

FF301 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00874 | 說明 | 香港聯交所上市 H 股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） | 2. 股份 ...

证券代码：600332 证券简称：白云山 公告编号：2026－010 广州白云山医药集团股份有限公司 关于子公司收购浙江省医药工业有限公司 100%股权的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 12 月 17 日，广州白云山医药集团股份有限公司（"本公司"）下属控股 子公司广州医药股份有限公司（"广州医药"）与浙江海正药业股份有限公司（"海 正药业"）签署了《浙江省医药工业有限公司股权交易合同》（"《股权交易合同》"） 以及《浙江省医药工业有限公司股权交易合同之补充协议》，广州医药通过公开摘牌 方式受让海正药业所持浙江省医药工业有限公司（"浙江医工"、"目标公司"）100% 股权，转让价款为人民币 50,050.00 万元。具体内容详见本公司于 2025 年 12 月 17 日 披露的编号为 2025-087 的公告。 二、本次交易的进展情况 截至本公告日，广州医药已按照《股权交易合同》的约定向海正药业支付了全部 股权转让款。浙江医工已完成上述事项工商变更登记手续，本次 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00874 | 說明 | 香港聯交所上市 H 股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 2. 股份 ...

二、本次交易的进展情况 2026 年 2 月 27 日，中国证券登记结算有限责任公司出具《证券过户登记确认书》， 本次交易已完成过户登记手续，过户日期为 2026 年 2 月 26 日。本次过户登记完成后， 广药二期基金持有南京医药 144,557,431 股无限售流通股，占南京医药目前总股本的 11.04%。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"）召开第九届 董事会第二十九次会议，审议通过了《关于广州广药二期基金股权投资合伙企业（有 限合伙）收购南京医药股份有限公司 11.04%股份的议案》。本公司附属企业广州广 药二期基金股权投资合伙企业（有限合伙）（"广药二期基金"）拟以自有资金通过协 议转让方式收购Alliance Healthcare Asia Pacific Limited持有的南京医药集团股份有限 公司（原南京医药股份有限公司已更名为南京医药集团股份有限公司，简称"南京医 药"）144,557,431 股非限售股份（"目标股份"），占南京医药股份总数的 11.04%（"本 次交易"）。具体内容详见本公司于 2025 年 9 月 29 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於廣州廣藥二期基金股權投資合夥企業（有限合伙）收購南京醫藥集團股份有限公司11.04% 股份的進展公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2026年2月27日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 海外監管公告 一、本次交易的基本情况 证券代码：600332 证券简称：白云山 公告编号：2026－009 广州白云山医药集团股份有限公司 关于广州广药二期基金股权投资合伙企业（有限合伙） 收购南京医药集团股份有限公司 11.04%股份的进展公告 本 ...

Core Viewpoint - The discussion revolves around the potential privatization of H-shares by companies like Baiyunshan, similar to the approach taken by Dongfang Automobile, to better reflect their enterprise value and enhance global influence [1]. Group 1: Company Actions - Dongfang Automobile has adopted a strategy of privatizing its H-shares and converting them into shares of Lantu Automobile, suggesting that the current stock price does not reflect the company's true value [1]. - Baiyunshan's H-shares have consistently traded below net asset value, prompting investor suggestions for a similar privatization strategy to enhance the value of Wanglaoji [1]. Group 2: Market Implications - The potential privatization of Baiyunshan's H-shares and conversion into Wanglaoji shares could not only reflect the true value of Wanglaoji but also strengthen its global expansion efforts [1]. - The listing of Jiaduobao in Hong Kong could pose a significant competitive threat to Wanglaoji if it were to pursue a similar listing strategy [1].

Core Viewpoint - The Guangdong Provincial High-Quality Development Conference emphasizes the theme of "coordinated development of manufacturing and service industries," aiming to stimulate economic growth and innovation in the region [1][2]. Group 1: Conference Highlights - The conference marks the fourth consecutive year of focusing on high-quality development, signaling that high-quality growth is a fundamental requirement rather than an option [2]. - The concept of "two-industry collaboration" is highlighted as a new direction for industrial development, particularly in the context of emerging technologies such as AI, biomanufacturing, and quantum communication [1][3]. Group 2: Company Initiatives - Guangzhou Pharmaceutical Group (广药集团) is actively pursuing modernization, technological advancement, digitalization, and internationalization to transform itself during the "14th Five-Year Plan" period [1][3]. - The company has made significant investments in technology innovation, establishing over 100 research platforms and engaging more than 25 dual-appointed academicians in the biopharmaceutical field [4][5]. Group 3: Strategic Goals - The company aims to become a technology-driven and innovative enterprise, moving beyond traditional pharmaceutical manufacturing to provide comprehensive health solutions [8]. - A commitment of 10 billion to 15 billion yuan in R&D investment is planned for the "14th Five-Year Plan" period, with an additional 20 billion to 30 billion yuan allocated for industrial investment and acquisitions [10]. Group 4: Market Expansion - The company plans to expand its international presence by targeting markets in Southeast Asia, the Middle East, and Europe, while also promoting its leading health beverage brand, WALOVI [11]. - The establishment of the Guangzhou Medical Device Export Comprehensive Service Platform exemplifies the "two-industry collaboration" approach, providing one-stop professional services for pharmaceutical enterprises [6].

Group 1 - Guangzhou Pharmaceutical Group has established a new capital company named Guangzhou Guangyao Capital Co., Ltd. with a registered capital of 2 billion yuan [1] - The business scope of the new company includes investment activities using its own funds and enterprise management consulting [1] - Guangzhou Guangyao Capital Co., Ltd. is wholly owned by Guangzhou Pharmaceutical Group Co., Ltd. [1]